Technicals Stability Returns

TopStockResearch Celebrates Glorious 75 years of Indian Independence

with Made in India Product to make you Atma Nirbhar
Fundamental Analysis of Torrent Pharmaceuticals (TORNTPHARM)

Summary    Balance Sheet    Cash Flow    Income    Qtrly Income    Valuation Ratio    Profitability Ratios    Solvency    Efficiency Ratios    

Guru Numbers
Book Value/Share351.89
EV/EBITDA12.71
Market Cap (Cr)53261.09
Enterprise Value (Cr)56876.09
Piotroski F-Score8.00
Altman Z Score6.18
Graham No612.12
Price/ Graham 2.57
Peter Lynch Ratio-1.14
Sloan Ratio-0.063
Peter Lynch Fair value284.46
Price/ Peter Lynch FV5.53
TSR Fair value2224.18
Key Financial ratios of TORNTPHARM
Ratio Latest FY Yoy Change TTM MRQ Screener/
About
Price to Earning    30.39 76.68 % 33.25    
Price to Book    3.97 7.52 % 4.41 8.95    
Price to Sales    2.78 1.68 % 3.09    
Earning Per Share    45.93 -37.91 % 47.32 10.46    
Return On Equity    13.05 -39.14 % 13.27 5.95    
Return On Asset    5.93 -33.32 % 5.92 2.70    
Net Profit Margin    9.13 -42.47 % 9.28 15.45    
Operating Profit Margin    15.09 -34.91 % 17.94 24.30    
EBITDA Margin    25.19 -21.80 % 25.11 32.37    
Debt to Equity Ratio    0.675 -18.80 % 0.675    
Current Ratio    1.20 6.24 % 1.20    
Quick Ratio    0.642 10.48 % 0.642    
View Historitcal ratios of Torrent Pharmaceuticals Ltd.
Valuation Ratios   Profitability Ratio   Solvency Ratios   Efficiency Ratios
Screen Financial Ratio using Custom Screener
Terrific View
Piotroski F Score - Excellent Value of 8.0
Altman Z Score of 6.18 suggests good Stability
Undervalued - Price to Intrinsic Value of 0.708
Debt to equity ratio has decreased and is lowest in last three years
Short term positive trend in total sale and net profit
Company Earning excess return
Steady View
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Company financial liquidity has improved
Book Value in last 3 years is trending up
Good Return on Equity of 13.27% is achieved by the company
Risky View
Tsr Value Index - Poor Score of 27.78
Tsr Growth Index - Very Poor Score of 16.15
Price to Book Ratio of 4.47 suggesting that it is very expensive
Low Earning Yield of 2.92 %
Company's Total Assets is Decreasing for last 3 years
Terrific Steady Risky Stock View - Fundamental Snapshot
Share Overview
Promoter Owned71.30 %
Institution Owned20.60 %
Public/Others8.10 %
Outstanding Shares33.84 Cr
Floating Shares9.69 Cr
Floating / Outstanding28.64%
Book Value/Share351.89
Face value5.00
Share Holding
Annual Key Income Statement of TORNTPHARM
Period 31_Mar_2022 31_Mar_2021 Growth
Net Income From Continuing Ops 777.00 1252.00 37.94 %
Net Income 777.00 1251.88 37.93 %
Operating Income 1284.00 1828.37 29.77 %
Total Revenue 8508.00 7886.23 7.88 %
Operating Expense 6650.00 3822.56 73.97 %
Interest Expense 255.00 356.16 28.40 %
Tax Expense 448.73 274.38 63.54 %
Income Before tax 1226.00 1526.26 19.67 %
Gross Profit 6065.00 5650.93 7.33 %
Dividend Paid -676.89 -338.00 100.26 %
   
Quarterly Key Income Statement of TORNTPHARM
Period 30_Jun_2022 31_Mar_2022 Growth
Net Income From Continuing Ops 354.00 -118.00 400.00 %
Net Income 354.00 -118.00 400.00 %
Operating Income 557.00 -86.00 747.67 %
Total Revenue 2292.00 2131.00 7.56 %
Operating Expense 1735.00 1710.00 1.46 %
Interest Expense 55.00 54.00 1.85 %
Tax Expense 178.00 30.73 479.24 %
Income Before tax 532.00 -87.00 711.49 %
Gross Profit 1632.00 1509.00 8.15 %
Dividend Paid 0 -677.00 100.00 %
   
Key Balance Sheet Fields
Period 31_Mar_2022 31-Mar-21 Growth
Common Stock 84.62 84.62 0 %
Current Liabilities 4415.09 4891.62 9.74 %
Total Liabilities 7147.00 8237.48 13.24 %
Current Assets 5294.65 5521.50 4.11 %
Total Assets 13100.00 14074.65 6.92 %
Working capital 879.56 629.88 39.64 %
Accounts Payable 1674.44 2066.81 18.98 %
Inventory 2462.32 2681.20 8.16 %
Net Receivable 1913.71 1889.36 1.29 %
   
Key Cash Flow Fields
Period 31_Mar_2022 31_Mar_2021 Growth
Cash EPS 83.89 112.87 25.68 %
Cash From Investment Activity -196.63 -449.42 56.25 %
Cash From Financial Activity -1781.05 -1656.00 7.55 %
Cash Operational Activity 1802.99 2011.00 10.34 %
Net Cash Flow -174.69 -94.42 85.01 %
NetIncome 777.00 1251.88 37.93 %
Capital Expenditure 202.57 335.00 39.53 %
Change To Inventory 218.88 -532.00 141.14 %
   



   About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also provides contract manufacturing services. It has licensing collaborations of Baricitinib, Molnupiravir, and Paxlovid for its Covid portfolio. Torrent Pharmaceuticals Limited was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Address : Torrent House, Ahmedabad, India, 380009

URL : https://www.torrentpharma.com

Employee Count : 12703

About TSR TECH Strength / Valuation / Growth

TSR Tech Strength is based on Deep Analysis, Back Testing and Historical Trend Analysis using Machine Learning. Overall Technical Strength is based on 50+ indicators including Technicals, moving Avg, chart patterns, candlestick and proprietary algorithms.Technical Strength is calculate from 5Mins Ticck to One Month Tick

TSR Growth analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access Growth Potential

TSR Value analyses dozen of Historical , MRQ, TTM parameters, returns of Individual Stocks vis-a-vis sector , broad based Index to access its value

This is an automated process and in NO WAY should be considered as a tip as its based on past data. We strongly recommend to use these signals for information only and seek advise from a certified professional for any trading decision.If you like it then please share. The more the visitors the more the innovations. Feedback

We are working on fundamental strength also. Please share your views to help shape up the requirement.